S
NBIX icon

SignatureFD’s Neurocrine Biosciences NBIX Stock Holding History

SignatureFD’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.8K Sell
583
-1,342
-70% -$178K ﹤0.01% 1483
2025
Q4 		$273K Buy
1,925
+83
+5% +$12K ﹤0.01% 822
2025
Q3 		$259K Buy
1,842
+9
+0.5% +$1.22K ﹤0.01% 826
2025
Q2 		$230K Sell
1,833
-607
-25% -$69.6K ﹤0.01% 846
2025
Q1 		$270K Sell
2,440
-361
-13% -$45.7K 0.01% 756
2024
Q4 		$382K Buy
2,801
+165
+6% +$20.4K 0.01% 614
2024
Q3 		$304K Sell
2,636
-88
-3% -$12.1K 0.01% 694
2024
Q2 		$375K Buy
2,724
+162
+6% +$22.2K 0.01% 591
2024
Q1 		$353K Buy
2,562
+51
+2% +$6.96K 0.01% 630
2023
Q4 		$331K Buy
2,511
+125
+5% +$14.4K 0.01% 615
2023
Q3 		$268K Buy
2,386
+1,990
+503% +$210K 0.01% 630
2023
Q2 		$37.3K Sell
396
-40
-9% -$3.91K ﹤0.01% 1578
2023
Q1 		$44.1K Buy
436
+151
+53% +$15.7K ﹤0.01% 1458
2022
Q4 		$34K Buy
285
+27
+10% +$3.16K ﹤0.01% 1547
2022
Q3 		$27K Sell
258
-26
-9% -$2.64K ﹤0.01% 1595
2022
Q2 		$28K Sell
284
-12
-4% -$1.11K ﹤0.01% 1609
2022
Q1 		$28K Buy
296
+42
+17% +$3.56K ﹤0.01% 1671
2021
Q4 		$22K Sell
254
-431
-63% -$39.6K ﹤0.01% 1747
2021
Q3 		$66K Sell
685
-2
-0.3% -$189 ﹤0.01% 1162
2021
Q2 		$67K Buy
687
+7
+1% +$671 ﹤0.01% 1132
2021
Q1 		$66K Sell
680
-14
-2% -$1.47K ﹤0.01% 1046
2020
Q4 		$67K Sell
694
-1,048
-60% -$101K ﹤0.01% 950
2020
Q3 		$168K Buy
1,742
+106
+6% +$12.3K 0.01% 548
2020
Q2 		$200K Buy
1,636
+74
+5% +$8.18K 0.01% 450
2020
Q1 		$135K Buy
1,562
+132
+9% +$12.9K 0.01% 530
2019
Q4 		$154K Buy
1,430
+81
+6% +$8.48K 0.01% 560
2019
Q3 		$122K Hold
1,349
– – 0.01% 573
2019
Q2 		$114K Buy
1,349
+10
+0.7% +$821 0.01% 575
2019
Q1 		$118K Hold
1,339
– – 0.01% 564
2018
Q4 		$96K Buy
1,339
+1
+0.1% +$96 0.01% 603
2018
Q3 		$165K Buy
1,338
+1,000
+296% +$113K 0.02% 473
2018
Q2 		$33K Hold
338
– – ﹤0.01% 1002
2018
Q1 		$28K Buy
+338
New +$28.5K ﹤0.01% 946
2016
Q4 		– Sell
-200
Closed -$10K – 854
2016
Q3 		$10K Hold
200
– – ﹤0.01% 1021
2016
Q2 		$9K Hold
200
– – ﹤0.01% 936
2016
Q1 		$8K Hold
200
– – ﹤0.01% 895
2015
Q4 		$11K Hold
200
– – ﹤0.01% 714
2015
Q3 		$8K Hold
200
– – ﹤0.01% 728
2015
Q2 		$10K Hold
200
– – ﹤0.01% 622
2015
Q1 		$8K Hold
200
– – ﹤0.01% 574
2014
Q4 		$4K Hold
200
– – ﹤0.01% 665
2014
Q3 		$3K Hold
200
– – ﹤0.01% 573
2014
Q2 		$3K Hold
200
– – ﹤0.01% 667
2014
Q1 		$3K Hold
200
– – ﹤0.01% 581
2013
Q4 		$2K Hold
200
– – ﹤0.01% 593
2013
Q3 		$2K Hold
200
– – ﹤0.01% 546
2013
Q2 		$3K Buy
+200
New +$2.46K ﹤0.01% 448

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SignatureFD's NBIX Position: Q1 2026 in Review

SignatureFD reduced its Neurocrine Biosciences (NBIX) stake by 70% in Q1 2026, selling an estimated $178K and leaving 583 shares worth $76.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1483.

SignatureFD first reported a position in NBIX in Q2 2013 and has held it in 47 quarters since. The position peaked at $382K in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • SignatureFD held 583 shares of Neurocrine Biosciences worth $76.8K as of Q1 2026.
  • SignatureFD sold 1,342 Neurocrine Biosciences shares in Q1 2026, an estimated $178K.
  • Neurocrine Biosciences made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #1483 holding.
  • SignatureFD first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 47 quarters since.
  • SignatureFD's Neurocrine Biosciences position peaked at $382K in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.